Synkrino Biotherapeutics Company
Synkrino Biotherapeutics is a biotech platform that discovers and develops novel drug targets directly from the immune system of patients. The platform is providing monitoring for pediatric rheumatologists for life-threatening conditions. It is currently building a rapid, portable field test for the RNA virus 2019-nCoV/COVID-19, adapting its existing analytic protocols for community public health screening. Synkrino Biotherapeutics' therapeutics use AI + Immunology Discovery Engine (AIDE Engine) which applies neural networks and machine learning to measure the immune tissue from patients to repeatably discover novel and biologically-valid drug targets, enabling healthcare providers to cure their patients and improve their lives.
Connections from
Technology:
AI-driven Drug Target Identification
Industry:
BioPharma AI
Founded Date:
2018
Headquarters:
Berkeley, California, United States
Funding Status:
Private